Home
HelpTest Code PNP Platelet Neutralization Procedure, Plasma
Useful For
Aiding in the confirmation or exclusion of the presence of a lupus anticoagulant (LAC) inhibitor when used in conjunction with other appropriate coagulation tests.
Aids in differentiating deficiencies or inhibitors of specific coagulation factors (eg, factor VIII inhibitor) from LAC inhibitors
Method Name
Only orderable as a reflex. For more information, see:
ALUPP / Lupus Anticoagulant Profile, Plasma
ALBLD / Bleeding Diathesis Profile, Limited, Plasma
AATHR / Thrombophilia Profile, Plasma and Whole Blood
APROL / Prolonged Clot Time Profile, Plasma
ADIC / Disseminated Intravascular Coagulation/Intravascular Coagulation and Fibrinolysis (DIC/ICF) Profile, Plasma
Optical Clot-Based
Reporting Name
Platelet Neutralization ProcedureSpecimen Type
Plasma Na CitSpecimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Plasma Na Cit | Frozen | ||
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Clinical Information
Prolonged clotting times may be due to a variety of factors including the presence of clotting factor deficiencies, factor inhibitors, and lupus anticoagulants (antiphospholipid antibodies).
When a prolonged activated partial thromboplastin time (APTT) demonstrates inhibition on mixing with normal plasma indicative of presence of an inhibitor, the platelet neutralization procedure (PNP) is useful in determining if this inhibition is due to presence of a lupus anticoagulant (LAC).
The PNP involves the addition of washed, freeze-thawed platelets or buffer to the patient's plasma. An APTT is done on both mixtures and the clotting times are compared. Additional phospholipid supplied by the PNP reagent can absorb LAC, thereby diagnostically shortening the APTT.
For performance and interpretation of the PNP, the baseline APTT should be significantly prolonged (preferably at least 3 to 5 seconds above the upper limit of the reference range), and APTT inhibition must be demonstrated or suggested by a mixing study with normal plasma (ie, 1:1 mix fails to shorten into the normal range).
Reference Values
Only orderable as a reflex. For more information see:
ALUPP / Lupus Anticoagulant Profile, Plasma
ALBLD / Bleeding Diathesis Profile, Limited, Plasma
AATHR / Thrombophilia Profile, Plasma and Whole Blood
APROL / Prolonged Clot Time Profile, Plasma
ADIC / Disseminated Intravascular Coagulation/Intravascular Coagulation and Fibrinolysis (DIC/ICF) Profile, Plasma
An interpretive report will be provided.
Interpretation
Interpretation of the results of the platelet neutralization procedure (PNP) test is complex and needs to be performed in the context of results of mixing study of the prolonged activated partial thromboplastin time (APTT), the APTT PNP and the buffer control APTT, as well as results of other coagulation tests (eg, prothrombin time and thrombin time as well as available clinical information).
Plasma containing lupus anticoagulant (LAC) will demonstrate shortening of the PNP Platelets APTT by 2 or more seconds when compared to the baseline PNP Saline APTT.
Cautions
The presence of heparin will cause a false-positive platelet neutralization procedure (PNP). The distinction is usually not difficult because the presence of heparin can be detected by a prolonged thrombin time and normal reptilase time.
The presence of coagulation factor V inhibitors or deficiency may also produce a false-positive PNP result. This can be suspected if the prothrombin time (PT) is significantly prolonged and may merit additional testing.
The presence of other coagulopathies or interfering conditions (causing false-positive PNP interpretation) should be evaluated by results of other tests (PT, thrombin time, and other assays if needed) and by available clinical information.
Method Description
The platelet neutralization procedure (PNP) assay is performed on the Instrumentation Laboratory ACL TOP. Two cuvette wells are tested: 1 containing patient plasma and buffer and the other containing patient plasma and PNP platelet reagent. The contents of each cuvette well are combined and incubated with an activated partial thromboplastin time reagent containing phospholipid, a negatively charged contact factor activator, and buffer. After a specified incubation time, calcium is added to trigger the coagulation process in the mixture. Subsequently, the time to clot formation is measured optically using a wavelength of 671 nm for each cuvette well.(Package insert: Cryocheck Platelet Lysate. Precision Biologic Inc.; 02/14/2011)
Day(s) Performed
Monday through Friday
Report Available
1 to 4 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| PNP | Platelet Neutralization Procedure | 103620-1 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| PNPPL | Platelet Neutralization Procedure | 75506-6 |
| PNPSA | PNP Buffer Control | 103619-3 |
Specimen Required
Only orderable as a reflex. For more information see:
ALUPP / Lupus Anticoagulant Profile, Plasma
ALBLD / Bleeding Diathesis Profile, Limited, Plasma
AATHR / Thrombophilia Profile, Plasma and Whole Blood
APROL / Prolonged Clot Time Profile, Plasma
ADIC / Disseminated Intravascular Coagulation/Intravascular Coagulation and Fibrinolysis (DIC/ICF) Profile, Plasma
Specimen Stability Information: Frozen 2 years
Specimen Minimum Volume
See Specimen Required
CPT Code Information
85597